Periocular Gene Transfer For Retinal and Choroidal Diseases

Peak revenue. Not a decision input — the asset is an expired method patent classified grant_non_commercial, so this is an illustrative cohort-consistency figure, not a forecast. It is deliberately anchored low to Luxturna's ~$250M lifetime ocular-gene-therapy reality (well below early blockbuster projections) plus modest upside for a larger neovascular population, explicitly NOT to the multi-billion anti-VEGF biologic market, because the periocular adenoviral route is superseded and the underlying method patent confers no exclusivity.

WACC. Ocular gene therapy carries above-baseline development risk (delivery, durability, immunogenicity) and this specific adenoviral-periocular route is a superseded, off-patent approach with a stalled clinical precedent, justifying a discount rate at the high end of the gene-therapy band.

This is not a therapeutic asset — it is an enabling-technology / delivery-route method patent. US Patent 7,989,426 (a divisional from the Campochiaro/Gehlbach Johns Hopkins ophthalmic gene-therapy program) claims a method of treating ocular neovascular disorders by periocular administration of a vector encoding an anti-angiogenic factor (the program's lead transgene was PEDF; sFlt-1 was a sibling). Critically, that patent expired 2023-02-14, so the method confers no remaining exclusivity. The rNPV envelope below is shown only for cohort consistency — the rNPV is not the decision criterion here, which is why the asset is classified grant_non_commercial; its real value, if any, is as prior art / a non-commercial scientific contribution, not a standalone-equity story. The underlying biology (sustained intraocular anti-angiogenesis via in-eye gene transfer) is sound and has since been validated by the field, but the specific adenoviral-periocular route this patent claims is superseded.

Comparator economics confirm the framing rather than support a forecast. The patent's own clinical embodiment — AdPEDF.11 (GenVec, NCT00109499) — reached a 28-patient Phase 1 in wet AMD in 2006 with acceptable safety and only suggestive efficacy, was never advanced into pivotal trials, and the sponsor was absorbed by Intrexon in 2017; it is a cautionary precedent, not a live anchor. The mechanism-true successor, ABBV-RGX-314 (AAV8 anti-VEGF, pivotal readouts expected 2026), shows the field has consolidated on AAV subretinal/suprachoroidal delivery, not adenoviral periocular injection. Luxturna anchors the ocular-gene-therapy regulatory pathway and a sobering commercial ceiling (~$250M lifetime, well below early projections). The engine result is -$62.3M to -$28.0M, with a base rNPV of -$45.2M and cumulative PoS of 3.7%; that wide, low spread is exactly what an expired-method, superseded-route, non-commercial classification should produce — not a fundable DCF.

Verdict: an honest grant_non_commercial / prior-art entry. It earns rank 26 on the rubric's neutral 0.5 whitespace ("other" indication), high IRA-exposure proxy, and a strong gene-therapy modality_pos score — it does NOT earn it as a fundable product, and that distinction is the entire point. A periocular gene-transfer method whose core patent has expired and whose clinical embodiment stalled at Phase 1 is a scientific-contribution / licensing-prior-art asset, not a VC-fundable one.